MFDS
- Marketing authorisation holder: ASCENDIS PHARMA BONE
- Status: likely_approved
🇰🇷 Yorvipath in South Korea
Yorvipath (PALOPEGTERIPARATIDE) regulatory status in South Korea.
Marketing authorisation
Yorvipath in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Nephrology approved in South Korea
Frequently asked questions
Is Yorvipath approved in South Korea?
Yes. MFDS has authorised it.
Who is the marketing authorisation holder for Yorvipath in South Korea?
ASCENDIS PHARMA BONE holds the South Korean marketing authorisation.